Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA.
Abdominal Transplant and HPB Surgical Oncology, Toronto General Hospital and Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON PMB-11-175, Canada.
Am J Hum Genet. 2024 Oct 3;111(10):2283-2298. doi: 10.1016/j.ajhg.2024.08.020. Epub 2024 Sep 18.
Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder of vascular malformations characterized by mucocutaneous telangiectases and arteriovenous malformations (AVMs) in internal organs. HHT is caused by inheritance of a loss of function mutation in one of three genes. Although individuals with HHT are haploinsufficient for one of these genes throughout their entire body, rather than exhibiting a systemic vascular phenotype, vascular malformations occur as focal lesions in discrete anatomic locations. The inconsistency between genotype and phenotype has provoked debate over whether haploinsufficiency or a different mechanism gives rise to the vascular malformations. We previously showed that HHT-associated skin telangiectases develop by a two-hit mutation mechanism in an HHT gene. However, somatic mutations were identified in only half of the telangiectases, raising the question whether a second-hit somatic mutation is a necessary (required) event in HHT pathogenesis. Here, we show that another mechanism for the second hit is loss of heterozygosity across the chromosome bearing the germline mutation. Secondly, we investigate the two-hit mutation mechanism for internal organ AVMs, the source of much of the morbidity of HHT. Here, we identified somatic molecular genetic events in eight liver telangiectases, including point mutations and a loss of heterozygosity event. We also identified somatic mutations in one pulmonary AVM and two brain AVMs, confirming that mucocutaneous and internal organ vascular malformations undergo the same molecular mechanisms. Together, these data argue that bi-allelic loss of function in an HHT gene is a required event in the pathogenesis of HHT-associated vascular malformations.
遗传性出血性毛细血管扩张症(HHT)是一种遗传性血管畸形疾病,其特征为黏膜皮肤毛细血管扩张和内脏动静脉畸形(AVMs)。HHT 是由三个基因中的一个功能丧失突变遗传引起的。尽管 HHT 患者在整个身体中都存在其中一个基因的单倍体不足,但并非表现出系统性血管表型,而是在离散的解剖位置出现局灶性血管畸形。基因型与表型之间的不一致性引发了关于单倍体不足或其他机制导致血管畸形的争论。我们之前曾表明,HHT 相关的皮肤毛细血管扩张症是通过 HHT 基因中的两次打击突变机制发展而来的。然而,仅在一半的毛细血管扩张症中鉴定出体细胞突变,这引发了一个问题,即第二次体细胞突变是否是 HHT 发病机制中的必要(必需)事件。在这里,我们表明,第二次打击的另一种机制是携带种系突变的染色体发生杂合性丢失。其次,我们研究了内脏 AVM 的两次打击突变机制,这是 HHT 发病的主要原因之一。在这里,我们鉴定了八个肝脏毛细血管扩张症中的体细胞分子遗传事件,包括点突变和杂合性丢失事件。我们还在一个肺 AVM 和两个脑 AVM 中鉴定出体细胞突变,证实了黏膜皮肤和内脏血管畸形经历相同的分子机制。总之,这些数据表明,HHT 基因的双等位基因功能丧失是 HHT 相关血管畸形发病机制中的必要事件。